| Stephen Y Nakada, MD | |
|
600 Highland Ave, Madison, WI 53792 | |
| (608) 263-4757 | |
| (608) 265-8852 |
| Full Name | Stephen Y Nakada |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 36 Years |
| Location | 600 Highland Ave, Madison, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801851415 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 36574 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Wi Hospitals & Clinics Authority | Madison, WI | Hospital |
| Divine Savior Healthcare | Portage, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Wisconsin Medical Foundation Inc | 6608785464 | 2164 |
News Archive
Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of its Stem Cell Colony Purification Application powered by the LEAP™ Cell Processing Workstation.
Meanwhile, McClatchy News reports that higher rates of mental illness and substance abuse among the newly enrolled will be a problem because there aren't enough therapists who accept Medicaid patients. Medicaid expansion developments in New Hampshire, North Dakota, Wyoming and Virginia are also covered.
Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.
› Verified 3 days ago
| Entity Name | University Of Wisconsin Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of its Stem Cell Colony Purification Application powered by the LEAP™ Cell Processing Workstation.
Meanwhile, McClatchy News reports that higher rates of mental illness and substance abuse among the newly enrolled will be a problem because there aren't enough therapists who accept Medicaid patients. Medicaid expansion developments in New Hampshire, North Dakota, Wyoming and Virginia are also covered.
Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Y Nakada, MD 7974 Uw Health Ct, Middleton, WI 53562-5531 Ph: () - | Stephen Y Nakada, MD 600 Highland Ave, Madison, WI 53792 Ph: (608) 263-4757 |
News Archive
Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of its Stem Cell Colony Purification Application powered by the LEAP™ Cell Processing Workstation.
Meanwhile, McClatchy News reports that higher rates of mental illness and substance abuse among the newly enrolled will be a problem because there aren't enough therapists who accept Medicaid patients. Medicaid expansion developments in New Hampshire, North Dakota, Wyoming and Virginia are also covered.
Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.
› Verified 3 days ago
Nathan Jung, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1821 S Stoughton Rd, Madison, WI 53716 Phone: 608-260-6000 Fax: 608-260-6881 | |
Dr. Daniel D Shapiro, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-4757 | |
Parth Shah, Urology Medicare: Medicare Enrolled Practice Location: Uw Hospitals & Clinics 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6400 | |
John D Wegenke, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1 S Park St, Madison, WI 53715 Phone: 608-287-2900 Fax: 608-287-2910 | |
Dr. Arthur Carl Plautz Jr., MEDICAL DOCTOR Urology Medicare: Not Enrolled in Medicare Practice Location: 6 Vicksburg Ct, Madison, WI 53718 Phone: 608-221-2374 Fax: 608-221-2374 | |
Dr. Brian Van Le, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5001 Lake Mendota Dr, Madison, WI 53705 Phone: 703-477-5514 | |
Dr. Edwin Jason Abel, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-4757 Fax: 608-265-8852 |